Week In Review: Sino Biopharm Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate

Sep. 26, 2022 2:50 AM ETBLTE, CASI, IVA, IVEVF, MRK, REGMF, SBHMY, SBMFF
ChinaBio Today profile picture
ChinaBio Today
2.1K Followers

Summary

  • Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal.
  • Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acquired 92.6% of Shanghai Teresa Healthcare, an electroporation company.
  • Beijing Biocytogen Pharma formed a strategic collaboration with Guangzhou FineImmune Biotech to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.

Female scientists working on virus vaccines

Orientfootage/iStock via Getty Images

Deals And Financings

Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm (OTCPK:SBMFF), in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva (IVA) in a $307 million deal (see

This article was written by

ChinaBio Today profile picture
2.1K Followers
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012. ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market. Visit: ChinaBio Today (http://www.chinabiotoday.com) ChinaBio LLC (http://www.chinabiollc.com)

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.